

Universal and High-fidelity DNA Single Nucleotide Polymorphism Detection based on CRISPR/Cas12a Biochip

Yong Chen^a, Yixin Mei^a, Xingyu Jiang^{ab*}

^a Department of Biomedical Engineering, Southern University of Science and Technology, No 1088, Xueyuan Rd., Xili, Nanshan District, Shenzhen, Guangdong, 518055, P. R. China

^b Shenzhen Bay Laboratory, Shenzhen, Guangdong 518055, China

Corresponding Author

E-mail: jiang@sustech.edu.cn

Table of Content

Figure S1	S2
Figure S2	S3
Figure S3	S4
Figure S4	S5
Figure S5	S6
Figure S6	S7
Figure S7	S8
Figure S8	S9
Table S1	S10
Table S2	S11
Table S3	S14
Table S4	S15
Table S5	S17
Table S6	S18
Table S7	S20
Table S8	S21




Figure S1. The gel electrophoretic results of the amplified products of the standard DNA using six designed primers. The results show that all six forward primers obtained the pure target band for the synthesized standard samples.




Figure S2. The gel electrophoresis results of the amplification products at different annealing temperatures indicate that the annealing temperature of 59 °C can further improve the amplification efficiency of primer No. 6.




Figure S3. The CRISPR/Cas12a system's detection results for standard samples do not distinguish the SNP genotype. The main reason is that Cas12a nuclease activated by complementary reverse ssDNA has no single nucleotide sensitivity.




Figure S4. The *trans*-cleavage rate of the CRISPR/Cas12a system under the different number of mismatched nucleotides between crRNA and target DNA. The result showed that the signal difference of the CRISPR/Cas12a system improved from 2-fold to nearly 10-fold when we introduced an addition nucleotide mismatch.




Figure S5. The CRISPR/Cas12a detection result under different concentrations of the Cas12a nuclease. These results indicated that the signal-to-noise ratio (SNR) of the CRISPR/Cas12a system significantly improved with the increasing dosage of the Cas12a nuclease.




Figure S6. The CRISPR/Cas12a detection result under different concentrations of the amplified product. These results indicated that the detection system is almost unaffected by the concentration of amplified products when the concentration of the Cas12a nuclease is excessive ($300\text{ nM} > 200\text{ nm}$, the theoretical maximum concentration of the amplified products in our experiment).




Figure S7. The three repeated genotyping results on the CRISPR/Cas12a biochip. These results indicated that the CRISPR/Cas12a biochip has good stability and reproducibility.




Figure S8. The gel electrophoresis results of the amplification products at different annealing temperatures for *CYP2C19*2* (G681A, rs4244285), *CYP2C9*3* (A1075C, rs1057910), *CYP2C19*3* (G636A, rs4986893) gene, respectively.

Table S1. SNP detection system for *CYP1A1* (A4889G, rs1048943) gene

rs1048943 A/A sequence	CACCCCTGATGGTGTATCGACAAGGTGTTAAGTGAGAAGGTGATTATCTTG GCATGGGCAAGCGGAAGTGTATCGGTGAGACC ATT GCCCCTGGGAGGTCTT TCTCTT
rs1048943 G/G sequence	CACCCCTGATGGTGTATCGACAAGGTGTTAAGTGAGAAGGTGATTATCTTG GCATGGGCAAGCGGAAGTGTATCGGTGAGACC G TGCCCCTGGGAGGTCTT TCTCTT
Forward Primer	AAGAGAAAGACCTCCCAGCGGGCAA
Forward Primer 1	AAGAGAAAGACCTCCCAGCG TT TA
Forward Primer 2	AAGAGAAAGACCTCCCAGCG TT AA
Forward Primer 3	AAGAGAAAGACCTCCCAG CT CAA
Forward Primer 4	AAGAGAAAGACCTCCCAG TT GCAA
Forward Primer 5	AAGAGAAAGACCTCCC TT GGCAA
Forward Primer 6	AAGAGAAAGACCTCCC TT GGCAA
Reverse Primer	CACCCCTGATGGTGTATCGACAAG
Forward Primer-L	CTACCTGAACGGTTCTCAC
Reverse Primer-L	CTGCATTGGAAGTGCTC
A-crRNA	UAAUUUCUACUAAGUGUAGAUCAA U GGUCUCACCGAUACAC
G-crRNA	UAAUUUCUACUAAGUGUAGAUCA A CGGUCUCACCGAUACAC
uA-crRNA	UAAUUUCUACUAAGUGUAGAU C U <u>UGGUCUCACCGAUACAC</u>
uG-crRNA	UAAUUUCUACUAAGUGUAGAU C U <u>G</u> GGUCUCACCGAUACAC
Tag ssDNA	FAM-TTTATT-BHQ1

Primers containing the PAM sequences are defined as forwarding primers.

The mutation site on the target DNA is marked by red.


The T bases introduced for PAM sequences are marked by green.


The mutation sites on crRNA are marked by blue.


The additional mismatches base on crRNA is marked orange "u".

"Forward Primer-L" and "Reverse Primer-L" were used to amplify 246 bp of long amplification products for reverse pyrosequencing.

Table S2. The result of CRISPR/Cas12a biochip and corresponding pyrosequencing of seventeen human blood samples for the *CYP1A1* (A4889G, rs1048943) gene.







The orange curve frame indicates the type of nucleotide at the mutation site.

The purple curve frame indicates the inserted PAM sequences.

The "forward/reverse primer-L" and "forward/reverse primer-PAM" were used for amplification and pyrosequencing.

The result indicated that the insertion of PAM sequences does not interfere with the genotypes.

Table S3. SNP detection system for *CYP2C19*2* (G681A, rs4244285) gene

rs4244285 G/G sequence	TTCCCACTATCATTGATTATTCGGGAACCCATAACAAATTACTTAAAAAC CTTGCTTTATGGAAAGTGATATTG
rs4244285 A/A sequence	TTCCCACTATCATTGATTATTCGGGAACCCATAACAAATTACTTAAAAAC CTTGCTTTATGGAAAGTGATATTG
Forward Primer	TTCCCACTATCATTGATTATTC
Reverse Primer	CCAAAATATCACTTCATAAAAGCAAG
Forward Primer-L	AATTACAACCAGAGCTTGGC
Reverse Primer-L	ATATCACTTCATAAAAGCAAG
uG-crRNA	UAAUUUCUACUAAGUGUAGAUC <u>G</u> GGAACCCAUACAAAUU
uA-crRNA	UAAUUUCUACUAAGUGUAGAUC <u>A</u> GGAACCCAUACAAAUU
Tag ssDNA	FAM-TTTATT-BHQ1

Primers containing the PAM sequences are defined as forwarding primers.

The mutation site on the target DNA is marked by red.


The T bases introduced for PAM sequences are marked by green.


The mutation sites on crRNA are marked by blue.

The additional mismatches base on crRNA is marked orange "u".

"Forward Primer-L" and "Reverse Primer-L" were used to amplify 168 bp of long amplification products for forward pyrosequencing.

Table S4. The result of CRISPR/Cas12a biochip and corresponding pyrosequencing of seventeen human blood samples for the *CYP2C19*2* (G681A, rs4244285) gene.





The orange curve frame indicates the type of nucleotide at the mutation site.

For pyrosequencing, the "Forward Primer-L" and "Reverse Primer-L" were used for amplification to obtain long sequences, so the pyrosequencing results did not contain PAM sequences.

Table S5. SNP detection system for *CYP2C9*3* (A1075C, rs1057910) gene

rs1057910 A/A sequence	CCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCTGCATGCAA GACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGAT ACATTGACCTTCTCCCCACCAGCCTGCC
rs1057910 C/C sequence	CCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCTGCATGCAA GACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGAT ACCTTGACCTTCTCCCCACCAGCCTGCC
Forward Primer	GGCAGGCTGGTGGGA TTT GGTCAA
Reverse Primer	CCAGGAAGAGATTGAACGTGTGATTG
uA-crRNA	UAAUUUCUACUAAGUGUAGAUGUCA <u>U</u> GUUAUCUCUGGACCU
uC-crRNA	UAAUUUCUACUAAGUGUAGAUGUCA <u>G</u> GUUAUCUCUGGACCU
Tag ssDNA	FAM-TTTATT-BHQ1

Primers containing the PAM sequences are defined as forwarding primers.


The mutation site on the target DNA is marked by red.


The T bases introduced for PAM sequences are marked by green.

The mutation sites on crRNA are marked by blue.

The additional mismatches base on crRNA is marked orange "u".

Table S6. The result of CRISPR/Cas12a biochip and corresponding pyrosequencing of seventeen human blood samples for the *CYP2C9*3* (A1075C, rs1057910) gene.





The orange curve frame indicates the type of nucleotide at the mutation site.

The purple curve frame indicates the inserted PAM sequences.

Table S7. SNP detection system for *CYP2C19*3* (G636A, rs4986893) gene

rs4986893 G/G sequence	ACATCAGGATTGTAAGCACCCCTGGATCCAGGTAAAGGCCAAGTTTTGCTT CCTGAGAAACCACCTACAGTCTTTCTGGAAATCCAAAATTCTATATTG ACCAAGCCCTGAAGTACAT
rs4986893 A/A sequence	ACATCAGGATTGTAAGCACCCCTGAATCCAGGTAAAGGCCAAGTTTTGCTT CCTGAGAAACCACCTACAGTCTTTCTGGAAATCCAAAATTCTATATTG ACCAAGCCCTGAAGTACAT
Forward Primer	ACATCAGGATTGTAAGTTTCCCCTG
Reverse Primer	ATGTACTTCAGGGCTTGGTCAATA
aG-crRNA	UAAUUUCUACUAAGUGUAGAUCCCuGAUCCAGGUAGGCC
aA-crRNA	UAAUUUCUACUAAGUGUAGAUCCCuAAUCCAGGUAGGCC
Tag ssDNA	FAM-TTTATT-BHQ1

Primers containing the PAM sequences are defined as forwarding primers.


The mutation site on the target DNA is marked by red.


The T bases introduced for PAM sequences are marked by green.

The mutation sites on crRNA are marked by blue.

The additional mismatches base on crRNA is marked orange "u".

Table S8. The result of CRISPR/Cas12a biochip and corresponding pyrosequencing of seventeen human blood samples for the *CYP2C19*3* (G636A, rs4986893) gene.





The orange curve frame indicates the type of nucleotide at the mutation site.

The purple curve frame indicates the inserted PAM sequences.